BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells 1,091 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 1,091 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $27,275.00. Following the completion of the sale, the insider now directly owns 58,816 shares in the company, valued at approximately $1,470,400. The trade was a 1.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Trading Down 0.2 %

Shares of BLFS stock opened at $25.00 on Friday. The business has a 50-day moving average price of $26.62 and a two-hundred day moving average price of $25.50. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.18 billion, a P/E ratio of -23.58 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the previous year, the company posted ($0.21) EPS. Equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BLFS shares. KeyCorp boosted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, HC Wainwright lifted their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $29.86.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently made changes to their positions in BLFS. Steward Partners Investment Advisory LLC bought a new stake in BioLife Solutions in the fourth quarter worth $26,000. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions during the third quarter valued at about $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of BioLife Solutions in the fourth quarter worth about $31,000. Quest Partners LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter valued at about $57,000. Finally, 1620 Investment Advisors Inc. lifted its stake in shares of BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 675 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.